Cargando…
Profile of omalizumab in the treatment of chronic spontaneous urticaria
Chronic spontaneous urticaria (CSU) is a disease with significant morbidity and relative prevalence that has important effects on the quality of life (QoL) of those who suffer from it. Omalizumab is a recombinant humanized anti-immunoglobulin E (IgE) antibody that binds to the Cε3 domain of the IgE...
Autores principales: | Labrador-Horrillo, Moises, Ferrer, Marta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554406/ https://www.ncbi.nlm.nih.gov/pubmed/26346472 http://dx.doi.org/10.2147/DDDT.S56004 |
Ejemplares similares
-
OMALIZUMAB IN TREATMENT-RESISTANT CHRONIC SPONTANEOUS URTICARIA
por: Godse, Kiran V
Publicado: (2011) -
Omalizumab is effective in the treatment of difficult-to-treat chronic spontaneous urticaria
por: Forgie, Jennifer, et al.
Publicado: (2014) -
Sex differences in the efficacy of omalizumab in the treatment of
chronic spontaneous urticaria
por: Sirufo, Maria Maddalena, et al.
Publicado: (2022) -
Omalizumab treatment for chronic spontaneous urticaria: data from Turkey
por: Kara, Rabia Oztas, et al.
Publicado: (2022) -
Use of biologics in chronic spontaneous urticaria – beyond omalizumab therapy?
por: Metz, Martin, et al.
Publicado: (2021)